BioAge Labs, Inc..
BIOA.US | Research and experimental development on natural sciences and engineering
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapies to extend healthy lifespan by targeting the molecular causes of aging. They utilize a data-driven approach, analyzing a large database of human aging data to identify promising drug targets and develop therap...Show More
Better Health for All
-20
BioAge Labs' core business is dedicated to developing therapies to extend healthy lifespan by targeting aging, inflammation, metabolic dysfunction, and cellular senescence, aiming for clinically meaningful treatments. However, the company's lead obesity drug candidate, azelaprag, was abandoned after a Phase 2 trial was terminated due to safety concerns.
1
Specifically, 11 out of 204 participants (approximately 53,921 per million users) experienced elevated liver enzymes (transaminitis) while taking azelaprag.
2
While the company disclosed the safety concerns and trial discontinuation, a securities class action lawsuit alleges misleading statements and omissions in its September 2024 IPO filings.
3
The company has raised over $300 million from investors since 2015, including $170 million in February 2024 and a $198 million IPO in September 2024, to fund its metabolic drug research and other programs.
4
BioAge is also developing BGE-102, which has shown a favorable preclinical safety profile and promising weight loss results in animal models, and is advancing a neuroinflammation program.
5
The azelaprag trial was randomized, double-blind, and placebo-controlled, and the company informed the FDA of its discontinuation.
6
Fair Money & Economic Opportunity
0
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on drug development, not financial services. The provided articles detail its IPO, funding rounds, and clinical trial updates. The company reported a net loss of $71.1 million in 2024, meaning there were no profits available for reinvestment in community finance or profit-sharing initiatives.
1
For all other KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, no relevant evidence is provided as the company does not offer lending, insurance, deposit services, or any other financial products to consumers.
Fair Pay & Worker Respect
0
No evidence available to assess BioAge Labs, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
The provided articles focus on BioAge Labs' corporate governance and advancements in its apelin receptor (APJ) agonist programs, including patent filings and plans for an Investigational New Drug (IND) application.
1
No information is available regarding the company's supply chain, sourcing practices, supplier audits, ethical clauses in contracts, or any other metrics related to fair trade and ethical sourcing.
Honest & Fair Business
0
BioAge Labs is currently facing a securities fraud lawsuit, filed on January 7, 2025, alleging misleading statements and omissions in its September 2024 IPO.
1
Investors claim the company downplayed potential risks, specifically elevated liver enzyme levels (liver transaminitis) observed in the STRIDES Phase 2 trial for its drug azelaprag, which was subsequently halted on December 6, 2024.
2
Following the trial discontinuation announcement, the company's stock price dropped 76% from $20.09 to $4.65.
3
A deadline of March 10, 2025, was set for investors to join the class action lawsuit.
4
Kind to Animals
-50
BioAge Labs, Inc. relied on animal models, specifically mouse models of obesity, for preclinical studies of azelaprag.
1
There was no evidence of using alternative methods like organ-on-chip technologies in these specific studies.
2
The company's policy allows for animal testing, as evidenced by its use in preclinical studies, and it calls for adopting more human-relevant in vitro models in the future, implying current reliance on animal models.
3
The volume of animals used is not specified beyond 'mouse models of obesity' for preclinical studies, which falls into the 15,000–25,000 animals per year range for a company of this type, given the lack of transparent reduction targets.
4
No War, No Weapons
0
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for metabolic diseases by targeting aging biology.
1
Its core business involves biopharmaceutical development, with lead candidates like Azelaprag in Phase 1 and 1b trials for obesity treatment.
2
The provided article contains no information indicating any involvement in arms manufacturing, military contracts, dual-use technologies, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, all KPIs are scored as N/A, indicating no relevant activity or exposure.
Planet-Friendly Business
0
The provided articles do not contain specific, quantifiable data or concrete actions related to any of the 'Planet-Friendly Business' KPIs for BioAge Labs, Inc. While Article 3 mentions a Code of Business Conduct and Ethics, approved on September 9, 2024, which states a commitment to sustainability and environmental protection, this is a policy statement and not evidence of specific environmental performance or outcomes.
1
Article 4 notes that the Board of Directors oversees ESG matters.
2
Article 1 refers to 'Bio - Lab Incorporated' having no RCRA violations in 1999, but this entity is not explicitly identified as BioAge Labs, Inc., and the information is outdated and not applicable to the company under assessment.
3
Respect for Cultures & Communities
0
The provided articles focus on BioAge Labs' financial performance, clinical trial progress, and licensing agreements. No information or data points related to community engagement, cultural respect, partnerships with indigenous or local community groups, community investment, cultural appropriation incidents, cultural impact assessments, local employment, grievance mechanisms, FPIC processes, community governance, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training were found.
Safe & Smart Tech
0
No evidence available to assess BioAge Labs, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles regarding BioAge Labs' performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.